Carmot Therapeutics Enters into Definitive Merger Agreement with Roche – Roche to acquire Carmot for an upfront payment of $2.7 billion and the potential for $400 million in milestone payments – – Carmot will join the Roche Group as part of Roche’s Pharmaceuticals...

Carmot Therapeutics Commenced Phase 2 Clinical Trial of Novel Dual GLP-1/GIP Receptor Agonist CT-868 for the Treatment of Type 1 Diabetes – Randomized, placebo-controlled trial to assess 16-week treatment with CT-868 in participants with overweight or obesity with type 1 diabetes (T1D) – – A second mechanistic clinical trial is...

Carmot Therapeutics Highlights Clinical Data from its Pipeline of Treatments for Obesity and Diabetes at ObesityWeek® – CT-388 administered once-weekly resulted in clinically meaningful weight loss and insulin sensitivity over a 4 week treatment period in participants with overweight or obesity without type 2...

Carmot Therapeutics Launches Spin-Off, Kimia Therapeutics, to Focus on Metabolic Disease – Spin-off of technology platform to newly-formed Kimia Therapeutics intended to maximize the full potential of Carmot’s metabolic portfolio while enabling Kimia to pursue a broad range of...